Table 2.
Results of base-case and scenario analysis.
| Strategy | Total cost$ | Incr cost$ | LY | QALY | Incr Eff | ICER$/QALYs |
|---|---|---|---|---|---|---|
| Base-case analysis | ||||||
| Sunitinib | 105,820 | NA | 4.41 | 2.97 | NA | NA |
| Nivolumab + cabozantinib | 358,764 | 252,943 | 5.34 | 3.84 | 0.86 | 292,945 |
| Scenario 1 | ||||||
| 5 years | ||||||
| Sunitinib | 75,520 | NA | 2.80 | 1.90 | NA | NA |
| Nivolumab + cabozantinib | 316,594 | 241,073 | 3.26 | 2.41 | 0.51 | 473,856 |
| 10 years | ||||||
| Sunitinib | 92,640 | NA | 3.71 | 2.51 | NA | NA |
| Nivolumab + cabozantinib | 340,961 | 248,321 | 4.45 | 3.23 | 0.72 | 343,900 |
| 15 years | ||||||
| Sunitinib | 101,064 | NA | 4.16 | 2.81 | NA | NA |
| Nivolumab + cabozantinib | 352,484 | 251,421 | 5.02 | 3.62 | 0.82 | 307,894 |
| Scenario 2 | ||||||
| Adjust nivolumab + cabozantinib 75% of its original price in the first-line setting | ||||||
| Sunitinib | 99,916 | NA | 4.41 | 2.97 | NA | NA |
| Nivolumab + cabozantinib | 290,413 | 190,498 | 5.34 | 3.84 | 0.86 | 220,623 |
| Adjust nivolumab + cabozantinib 50% of its original price in the first-line setting | ||||||
| Sunitinib | 94,011 | NA | 4.41 | 2.97 | NA | NA |
| Nivolumab + cabozantinib | 222,063 | 128,052 | 5.34 | 3.84 | 0.86 | 148,302 |
| Adjust nivolumab + cabozantinib 25% of its original price in the first-line setting. | ||||||
| Sunitinib | 88,106 | NA | 4.41 | 2.97 | NA | NA |
| Nivolumab + cabozantinib | 153,712 | 65,606 | 5.34 | 3.84 | 0.86 | 75,981 |
| Scenario 3 | ||||||
| Distribution of OS using parametric survival model | ||||||
| Sunitinib | 105,820 | NA | 4.41 | 2.97 | NA | NA |
| Nivolumab + cabozantinib | 358,764 | 252,943 | 5.34 | 3.84 | 0.86 | 292,945 |
| Distribution of OS using mixture cure model | ||||||
| Sunitinib | 115,260 | NA | 4.91 | 3.30 | NA | NA |
| Nivolumab + cabozantinib | 375,157 | 259,897 | 6.19 | 4.40 | 1.10 | 235,788 |
| Distribution of OS using nonmixture cure model | ||||||
| Sunitinib | 117,410 | NA | 5.02 | 3.38 | NA | NA |
| Nivolumab + cabozantinib | 366,762 | 249,352 | 5.75 | 4.11 | 0.74 | 337,891 |
| Distribution of OS using Royston/Parmar spline model | ||||||
| Sunitinib | 111,675 | NA | 4.72 | 3.18 | NA | NA |
| Nivolumab + cabozantinib | 365,818 | 254,143 | 5.71 | 4.08 | 0.90 | 281,321 |
LY, life year; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.